Searchable abstracts of presentations at key conferences in endocrinology

ea0029p608 | Diabetes | ICEECE2012

The antropometric characteristic of type 1 diabetic patients in Kragujevac

Mladenovic V. , Djukic A. , Petrovic J. , Sipetic S.

Background: Diabetes mellitus is a condition of chronic hyperglicemia (as well as metabolic disorders of the other carbohydrates, lipids and proteins), as a result of absolute and/or relative lack of insulin or lack of insulin effects. The aim of the research presented in this study is examination of antropometric characteristics of patients suffering from type 1 diabetes in Kragujevac depending on gender.Material and method: We examined 206 patients wit...

ea0029p611 | Diabetes | ICEECE2012

The antropometric characteristic of type 2 diabetic patients in Kragujevac

Petrovic J. , Mladenovic V. , Djukic A. , Sipetic S.

Introduction: Diabetes mellitus is a condition of chronic hyperglicemia (as well as metabolic disorders of the other carbohydrates, lipids and proteins), as a result of absolute and/or relative lack of insulin or lack of insulin effects.The aim of the research presented in this study is examination of antropometric characteristics of people suffering from type 2 diabetes in Kragujevac.Material and method: We examined 3108 patients ...

ea0029p633 | Diabetes | ICEECE2012

Prevalence of Charchot arthropathy after the introduction of electronic foot ulcer patient record

Marolt I , Kosmina Novak V , Mankoc S

Introduction: Loss of protective sensation, inflammation and trauma may lead in predisposed diabetics with peripheral neuropathy to Charcot foot.Methods: Regular foot screening enables identification of those individuals who are at highest risk for foot ulceration. Special attention must be paid to infection. Differentiation between osteomyelitis and Charcot arthropathy is mandatory, the two conditions may coexist. Basic conservative treatment for Charco...

ea0029p705 | Diabetes | ICEECE2012

GLP-1 agonists enhance stress-induced corticosterone release

Volke V. , Runkorg K. , Krass M.

Introduction: Currently, there are two glucagon-like peptide 1 (GLP-1) receptor agonists approved for the treatment of type 2 diabetes.While the primary pharmacological actions of GLP-1 agonists are antihyperglycaemic effect and weight reduction, these drugs may influence other neural and hormonal processes. Animal studies have indicated that GLP-1 receptors are involved in the regulation of stress, anxiety, learning and memory as well as regulation of c...

ea0029p735 | Diabetes | ICEECE2012

Differences in health related resource use and costs before and in 24 months after insulin initiation in patients with type 2 diabetes: final data from instigate study

Aloumanis K. , Benroubi M. , Drossinos V. , Polydorakis A.

Aims: We present final Hellenic data from the INSTIGATE study on direct costs of care and resource use, over the 24 months after insulin initiation, in type 2 diabetic (T2D) patients.Methods: INSTIGATE, a prospective European observational study involving T2D patients who initiated insulin during usual care, assessed direct costs of care over the 6 months prior to and for the intervals from baseline to 6 months, 6–12, 12–18 and 18–24 month...

ea0029p1257 | Obesity | ICEECE2012

Relationships between metabolic syndrome components and bone mineral density in ukrainian postmenopausal women

Martynyuk L. Povoroznyuk V. , Martynyuk L.

Objective: Postmenopausal period in women is associated with the accelerated bone loss, contributing to the development of osteoporosis, fractures and decreasing of quality and duration of life. The metabolic syndrome (MS), which includes obesity, dyslipidemia, hyperglycemia, and hypertension, is a major public health problem also.The purpose of our study was to reveal associations between tissue body composition, compounds of MS and BMD in postmenopausa...

ea0029p1547 | Steroid metabolism + action | ICEECE2012

Conversion of 7α-hydroxyDHEA into 7-ketoDHEA: Role of type 2 11β-hydroxysteroid dehydrogenase

Ngo-Duy C. , Labrie F. , Luu-The V.

It has been suggested that DHEA metabolites, especially 7-hydroxy and/or 7-keto derivatives could possess anti-inflammatory activity and enhance immune, cognitive and metabolic functions in rodents. It is thus important to elucidate the exact pathway (s) leading to the formation of these metabolites. While the role of cytochrome P450 CYP7B1 in the transformation of DHEA into 7α-OHDHEA is well recognized, the role of type 1 11β-hydroxysteroid dehydrogenase (11β-H...

ea0026p316 | Obesity | ECE2011

Identification of a reliable biomarker for metabolic syndrome

Abdullah A R , Hasan H , Raigangar V

Introduction: Over the last decade there has been a steady rise in obesity and co-morbidity, but little is known about the rate of metabolic dysfunction among young adults in the United Arab Emirates. Various factors have been implicated as biomarkers of metabolic syndrome (MetS). The objective of this study was to analyze the relationships of various biomarkers (leptin, C-reactive protein (CRP), adiponectin, insulin, and uric acid) to the MetS components in lean, overweight, ...

ea0026p688 | Diabetes complications | ECE2011

The risk factors for cardiovascular disease in type 2 diabetes patients

Mladenovic V , Djukic A , Petrovic J , Sipetic S

Introduction: Diabetes mellitus is equivalent of coronary artery disease (CAD), plenty of patients with CAD already has diabetes or prediabetes. Diabetes originate as result of interactions between diferent factors, like genetic and environment. The risk fatctors for type 2 diabetes are: positive family history for type 2 diabetes, obesity, age over 45 years, previous glucose intolerance or impaired fasting glucose, previous gestational diabetes or birthweight of children over...

ea0021p377 | Thyroid | SFEBES2009

An unusual presentation of hyperthyroidism

Holmes Simon , Prabhakar V K B

An 83-year-old gentleman was referred to the endocrine clinic with incidentally found abnormal thyroid function tests (TFT): TSH <0.02 (0.2–4.0 mU/l), free T4 20.4 (9–19 pmol/l), and free T3 7.6 (2.5–5.7 pmol/l). His TFT done 6 months previously were normal with TSH 1.21 mU/l and FT4 11.8 pmol/l. His past medical history included BPH, peripheral vascular disease and chronic kidney disease (CKD), and medications were tamsulosi...